- Home
- DLTH vs ACRS Comparison
DLTH vs ACRS Comparison
Compare DLTH & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLTH
- ACRS
- Stock Information
- Founded
- DLTH 1989
- ACRS 2012
- Country
- DLTH United States
- ACRS United States
- Employees
- DLTH N/A
- ACRS N/A
- Industry
- DLTH Clothing/Shoe/Accessory Stores
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- DLTH Consumer Discretionary
- ACRS Health Care
- Exchange
- DLTH Nasdaq
- ACRS Nasdaq
- Market Cap
- DLTH 134.2M
- ACRS 132.0M
- IPO Year
- DLTH 2015
- ACRS 2015
- Fundamental
- Price
- DLTH $3.26
- ACRS $2.72
- Analyst Decision
- DLTH Hold
- ACRS Strong Buy
- Analyst Count
- DLTH 1
- ACRS 5
- Target Price
- DLTH $3.50
- ACRS $8.75
- AVG Volume (30 Days)
- DLTH 66.5K
- ACRS 1.1M
- Earning Date
- DLTH 12-05-2024
- ACRS 11-06-2024
- Dividend Yield
- DLTH N/A
- ACRS N/A
- EPS Growth
- DLTH N/A
- ACRS N/A
- EPS
- DLTH N/A
- ACRS N/A
- Revenue
- DLTH $630,972,000.00
- ACRS $27,079,000.00
- Revenue This Year
- DLTH $0.66
- ACRS N/A
- Revenue Next Year
- DLTH $0.67
- ACRS N/A
- P/E Ratio
- DLTH N/A
- ACRS N/A
- Revenue Growth
- DLTH N/A
- ACRS 26.35
- 52 Week Low
- DLTH $3.09
- ACRS $0.86
- 52 Week High
- DLTH $5.82
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- DLTH 33.43
- ACRS 41.17
- Support Level
- DLTH $3.25
- ACRS $2.91
- Resistance Level
- DLTH $3.44
- ACRS $3.29
- Average True Range (ATR)
- DLTH 0.14
- ACRS 0.29
- MACD
- DLTH -0.02
- ACRS -0.18
- Stochastic Oscillator
- DLTH 3.50
- ACRS 0.75
About DLTH Duluth Holdings Inc. Class B
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar Mocs, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.